Urinary Bladder Neoplasms
3 competing products in clinical development for Urinary Bladder Neoplasms.
Pipeline by Phase
Phase 12
Phase 31
All Products (3)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Nivolumab + Gemcitabine + Cisplatin | Ono Pharmaceutical | Phase 3 | Active | 44 |
| Enfortumab vedotin | Astellas Pharma | Phase 1 | Terminated | 21 |
| E7766 | Eisai | Phase 1 | Withdrawn | 21 |